N-terminal pro-B-type natriuretic peptide: An independent marker for coronary artery disease in asymptomatic diabetic patients

Diabetic Medicine

Volumn 26, Issue 9, 2009, Pages 872-879

  Cosson, E ^a,b   Nguyen, M T ^b   Pham, I ^b   Pontet, M ^a   Nitenberg, A ^b   Valensi, P ^b  

^a HÔPITAL JEAN VERDIER   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

Coronary artery disease; Echocardiography; N terminal pro B type natriuretic peptide; Silent myocardial ischaemia; Type 2 diabetes

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN A1C;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE MARKER; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART SCINTISCANNING; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; SILENT MYOCARDIAL INFARCTION; STATISTICAL ANALYSIS;

BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 69249197868     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02788.x     Document Type: Article

References (32)

1. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ. Screening for coronary artery disease in patients with diabetes. Diabetes Care 2007 30 : 2729 2736.
2. Puel J, Valensi P, Vanzetto G, Lassmann-Vague V, Monin JL, Moulin P et al. Identification of myocardial ischemia in the diabetic patient. Joint ALFEDIAM and SFC recommendations. Diabetes Metab 2004 30 : 3S3 3S18.
3. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care 2003 26 : 1313 1314. (Pubitemid 36929292)
4. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events? Diabetes Metab 2003 29 : 470 476.
5. Faglia E, Manuela M, Antonella Q, Michela G, Vincenzo C, Maurizio C et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J 2005 149 : e1 e6.
6. Choi EK, Koo BK, Kim HS, Cho YM, Kang HJ, Cho YS et al. Prognostic significance of asymptomatic coronary artery disease in patients with diabetes and need for early revascularization therapy. Diabet Med 2007 24 : 1003 1011.
7. Fowler-Brown A, Pignone M, Pletcher M, Tice JA, Sutton SF, Lohr KN. Exercise tolerance testing to screen for coronary heart disease: a systematic review for the technical support for the US Preventive Services Task Force. Ann Intern Med 2004 140 : W9 W24.
8. Redberg RF, Greenland P, Fuster V, Pyorala K, Blair SN, Folsom AR et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group III: risk assessment in persons with diabetes. Circulation 2002 105 : e144 e152.
9. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. J Am Med Assoc 2009 301 : 1547 1555.
10. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006 92 : 843 849.
11. Albertini JP, Cohen R, Valensi P, Sachs RN, Charniot JC. B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients. Diabetes Metab 2008 34 : 355 362.
12. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK. Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart 2004 90 : 866 870.
13. Staub D, Jonas N, Zellweger MJ, Nusbaumer C, Wild D, Pfisterer ME et al. Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia. Am J Med 2005 118 : 1287.
14. Vanzetto G, Jacon P, Calizzano A, Neuder Y, Faure P, Fagret D et al. N-terminal pro-brain natriuretic peptide predicts myocardial ischemia and is related to post-ischemic left-ventricular dysfunction in patients with stable coronary artery disease. J Nucl Cardiol 2007 14 : 835 842.
15. Nicholls MG, Frampton CM, Yandle TG. BNP: not just for heart failure. Heart 2008 94 : 6 7.
16. Rana BS, Davies JI, Band MM, Pringle SD, Morris A, Struthers AD. B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart 2006 92 : 916 920.
17. Sakai H, Tsutamoto T, Ishikawa C, Tanaka T, Fujii M, Yamamoto T et al. Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP secretion and extent of coronary artery stenosis in patients with stable coronary artery disease. Circ J 2007 71 : 499 505. (Pubitemid 46513455)
18. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005 48 : 156 163.
19. Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006 49 : 2256 2262.
20. Cosson E, Paycha F, Paries J, Cattan S, Ramadan A, Meddah D et al. Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy? Diabet Med 2004 21 : 342 348.
21. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989 2 : 358 367.
22. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978 58 : 1072 1083.
23. Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988 12 : 426 440.
24. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 : 383 393. (Pubitemid 36159355)
25. Nitenberg A, Ledoux S, Valensi P, Sachs R, Antony I. Coronary microvascular adaptation to myocardial metabolic demand can be restored by inhibition of iron-catalyzed formation of oxygen free radicals in type 2 diabetic patients. Diabetes 2002 51 : 813 818.
26. Cosson E, Pham I, Valensi P, Paries J, Attali JR, Nitenberg A. Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. Diabetes Care 2006 29 : 107 112.
27. Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007 30 : 2934 2939.
28. Wong KY, McSwiggan S, Kennedy NS, MacWalter RS, Struthers AD. B-type natriuretic peptide identifies silent myocardial ischaemia in stroke survivors. Heart 2006 92 : 487 489.
29. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004 18 : 1928 1930.
30. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 2004 109 : 2872 2877.
31. McClure SJ, Gall S, Schechter CB, Kearney M, Zaman AG. Percutaneous coronary revascularization reduces plasma N-terminal pro-B-type natriuretic peptide concentration in stable coronary artery disease. J Am Coll Cardiol 2007 49 : 2394 2397.
32. Casco VH, Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MM, de Bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002 50 : 799 809.